Abstract
Although tumefactive multiple sclerosis is a well recognized variant of multiple sclerosis, prognostic uncertainty still exists about long term prognosis. The aim of this study was to estimate the occurrence and long term outcome of tumefactive demyelinating lesions (TDLs) in a cohort of multiple sclerosis patients. We reviewed brain MRI of 443 patients referred to our MS clinic. All patients meeting the McDonald criteria for multiple sclerosis and showing at least one TDL were included. Kaplan–Meier estimates of disease-free survival in patient cohort were compared with control group without TDLs using a log-rank test. Seven cases with TDLs were identified (occurrence 1.58 %). Tumefactive demyelinating lesion recurrence was 16.6 %. Cumulative proportion of patients free from clinical relapse and from new T2 lesions was lower in the control group although not reaching statistical significance (30 vs 50 %; P = 0.666 and 21.7 vs 33.3 %; P = 0.761, respectively). Disability progression analysis showed a not significant trend towards lower probability of remaining progression free for TDL patients (50 vs 61 %; P = 0.295). Occurrence of tumefactive demyelinating lesions in our cohort was higher than those reported in other studies. Overall, TDLs were not predictive of poor outcome in terms of disability progression.
Similar content being viewed by others
References
Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annal Neurol 69:292–302
Charil A, Yousry TA, Rovaris M et al (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol 5:841–852
Marsecano C, Perri M, Michelini G et al (2015) Vascular malformation mimicking multiple sclerosis active plaque: usefulness of susceptibility weighted imaging (SWI) to perform correct diagnosis. Neuroradiol J 28:488–492
Ciccarelli O, Miller DH (2002) Magnetic resonance imaging in multiple sclerosis. Pract Neurol 2:103–112
Hardy TA, Chataway J (2013) Tumefactive demyelination: an approach to diagnosis and management. JNNP 0:1–7
De Medeiros FC, De Albuquerque LAF, Pittella JEH et al (2014) Open-ring enhancement in pseudotumoral multiple sclerosis: important radiological aspect. Case Rep Neurol Med 2014:951690
Ernst T, Chang L, Walot I et al (1998) Physiologic MRI of a tumefactive multiple sclerosis lesion. Neurology 51:1486–1488
Selkirk SM, Shi J (2005) Relapsing-remitting tumefactive multiple sclerosis. Mult Scler 11:731–734
Law M, Meltzer D, Cha S (2002) Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology 44:986–989
Tsui EYK, Leung WH, Chan JH et al (2002) Tumefactive demyelinating lesions by combined perfusion-weighted and diffusion weighted imaging. Comput Med Imaging Graph 26:343–346
Findling O, Sellner J, Ozdoba C et al (2007) Tumefactive lesion in multiple sclerosis. Acta Neurol Belg 107:134
Kaeser MA, Scali F, Lanzisera FP et al (2011) Tumefactive multiple sclerosis: an uncommon diagnostic challenge. J Chiropr Med 10:29–35
Khoshyomn S, Braff S, Penar P (2002) Tumefactive multiple sclerosis plaque. JNNP 73:85
Malhotra HS, Jain KK, Agarwal A et al (2009) Characterization of tumefactive demyelinating lesions using MR imaging and in vivo proton MR spectroscopy. Mult Scler 15:193–203
Saini J, Chatterjee S, Thomas B et al (2011) Conventional and advanced magnetic resonance imaging in tumefactive demyelination. Acta Radiol 52:1159–1168
Lucchinetti CF, Gavrilova RH, Metz I et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775
Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
Kuan YC, Wang KC, Yuan WH et al (2013) Tumefactive multiple sclerosis in Taiwan. PLoS One 8:e69919
Kiriyama T, Kataoka H, Taoka T et al (2011) Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21(2):e69–e77
Totaro R, Di Carmine C, Carolei A (2014) Tumefactive demyelinating lesions in patients with relapsing remitting multiple sclerosis treated with Fingolimod. J Neurol Neurophysiol S12:006. doi:10.4172/2155-9562.S12-006
Kira J, Kanai T, Nishimura Y et al (1996) Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 40:569–574
Paty DW, Oger JJ, Kastrukoff LF et al (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180–185
Hunter S, Ballinger W, Rubin J (1987) Multiple sclerosis mimicking primary brain tumor. Arch Pathol Lab Med 111:464–468
Annesley-Williams D, Farrell MA, Staunton H et al (2000) Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropathol Exp Neurol 59:477–489
Altintas A, Petek B, Isik N et al (2012) Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 18:1448–1453
Beniac DR, Wood DD, Palaniyar N et al (1999) Marburg’s variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun 1:48–51
Wood DD, Bilbao JM, O’Connors P et al (1996) Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 40:18–24
Kepes J (1993) Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis: a study of 31 patients. Ann Neurol 33:18–27
Hayashi T, Kumabe T, Jokura H et al (2003) Inflammatory demyelinating disease mimicking malignant glioma. J Nucl Med 44:565–569
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Totaro, R., Di Carmine, C., Splendiani, A. et al. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis. Neurol Sci 37, 1113–1117 (2016). https://doi.org/10.1007/s10072-016-2558-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-016-2558-1